Balance Sheet

Accounts Payables Accumulated Expenses Assets Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Convertible Debt Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Deferred Tax Assets Current Leases Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Non-Current Deffered Revenue Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Pension Preferred Shares Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Supernus Pharmaceuticals (SUPN) Receivables - Other (2024 - 2026)

Supernus Pharmaceuticals has reported Receivables - Other over the past 5 years, most recently at $1.8 million for Q4 2025.

Quarterly Receivables - Other fell 55.0% to $1.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.8 million through Dec 2025, down 55.0% year-over-year, with the annual reading at $1.8 million for FY2025, 55.0% down from the prior year.
Receivables - Other was $1.8 million for Q4 2025 at Supernus Pharmaceuticals, down from $6.3 million in the prior quarter.
Over five years, Receivables - Other peaked at $6.3 million in Q3 2025 and troughed at $1.8 million in Q4 2025.